**To:** All Dartmouth Health Providers

**From:** Gregory J. Tsongalis, PhD, HCLD Director, CGAT

Laura J. Tafe, MD, Assistant Director, CGAT

Joel A. Lefferts, PhD, Assistant Director, CGAT

Eric Loo, MD, Assistant Director, CGAT

Wahab Khan, PhD, Assistant Director, CGAT

Samantha Allen, Supervisor, CGAT

Mohammad Azim, Supervisor, CGAT

Heather Steinmetz, CLSp (MB), Manager, CGAT

**Date:** November 28, 2022


**RE:** Somatic whole exome sequencing (sWES) DHCancerSeq v1

Beginning November 21, 2022, the DHMC Department of Pathology and Laboratory Medicine’s Laboratory for Clinical Genomics and Advanced Technology (CGAT) switched solid tumor NGS testing from the current TruSight 170 gene panel to a somatic whole exome sequencing assay, so called, DHCancerSeq v1 and new bioinformatics pipeline for reporting. The gene content will initially be comparable to the 170 gene panel and will expand over time to provide even more information with regards to the selection of targeted and immuno-therapies as well as be more pertinent to additional tumor types not currently being sequenced. CGAT faculty have been addressing the needs of the different Clinical Oncology Groups (COGs) during scheduled Tumor Board meetings and all DHCancerSeq v1 patient results are eligible for discussion at the Molecular Tumor Board held monthly. All ordering and reporting will remain similar although the report format will change.


eDH orderable:

* There is no change to the ordering of this test.

eDH view:







**For questions or additional information, please contact:** Samantha Allen, CLSp (MB), CGAT Supervisor, extension 5-8220; Heather Steinmetz, CLSp (MB), CGAT Manager, extension 5-8202; Laura J. Tafe, MD, CGAT Assistant Director, extension 5-7211; Gregory J. Tsongalis, PhD, CGAT Director, extension 5-5498.